🟢 Connect Biopharma is trading 5.5% up in after-hours trading as COPD trial cut failures by 81%

Connect Biopharma is trading $1.16 (+5.45%) after positive preliminary Phase 2 results showed rademikibart reduced COPD treatment failure by 81% through Week 4 versus placebo.

• On September 30, 2026, the company also reported 85% fewer new moderate-to-severe exacerbations and 100% fewer related hospitalizations or emergency visits.
• Connect Biopharma plans to discuss a Phase 3 program with the FDA.